SERPINA3
Alpha-1-antichymotrypsin
Protein Summary
Although its physiological function is unclear, it can inhibit neutrophil cathepsin G and mast cell chymase, both of which can convert angiotensin-1 to the active angiotensin-2. The protein encoded by this gene is a plasma protease inhibitor and member of the serine protease inhibitor class. Polymorphisms in this protein appear to be tissue specific and influence protease targeting. Variations in this protein's sequence have been implicated in Alzheimer's disease, and deficiency of this protein has been associated with liver disease. Mutations have been identified in patients with Parkinson disease and chronic obstructive pulmonary disease. [provided by RefSeq, Jul 2008]
- ENST00000393078
- ENSP00000376793
- ENSG00000196136
- ENST00000393080
- ENSP00000376795
- ENST00000467132
- ENSP00000450540
- ENST00000556968
- ENSP00000452476
- AACT
- ACT
- AACT
- GIG24
- GIG25
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
gene perturbation | 0.95 | ||
disease | 0.83 | ||
disease perturbation | 0.83 | ||
small molecule perturbation | 0.77 | ||
transcription factor perturbation | 0.74 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 1482.03 (req: < 5)
Gene RIFs: 81 (req: <= 3)
Antibodies: 255 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 1482.03 (req: >= 5)
Gene RIFs: 81 (req: > 3)
Antibodies: 255 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 9
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0